The Duke Regional Biocontainment Laboratory (RBL) was established with funding from the National Institutes of Health (NIH) to support basic research focused on developing drugs, diagnostics, and vaccines for emerging and reemerging infections, as well as for biodefense. The RBL features a comprehensive safety and operations program and provides state-of-the-art biocontainment facilities for both BSL-2 and BSL-3 research. Since its commissioning in 2007, the RBL has received partial support for construction and renovations from the NIH (UC6-AI058607 and G20-AI167200), as well as facility support through NIH award UC7-AI180254.
The Duke RBL supports a wide range of basic research programs and houses three collaborative core units: Immunology, Pathogens, and Animal Models. These units operate as fee-for-service centers available to Duke faculty and their collaborators. Through any of the cores, users can receive safety and security training and access to the containment environment. Each unit may be used independently or integrated to provide comprehensive study support, including regulatory compliance, study design, experimental execution, and data analysis.
| Herman Staats, PhD | Director |
| Scott Alderman, MS | Associate Director |
| Brook Heaton, PhD | Assistant Director |
| Hours | Location |
|
Monday - Friday |
909 S. LaSalle St. |
| Name | Role | Phone | Location | |
|---|---|---|---|---|
| RBL General Contact |
HVI-RBLInfo@dm.duke.edu
|